Zhaoke Ophthalmology Limited Board announced that the last patient last visit was completed for the one-year Phase III bridging clinical trial (Mini-CHAMP) of one of the Company's core products, NVK002 for the treatment of myopia, on August 3, 2023. The Company has been conducting a parallel two-year Phase III clinical trial (China CHAMP). The main objective of China CHAMP and Mini-CHAMP is to evaluate the efficacy and safety of NVK002 (low dose atropine 0.01% and 0.02%) in the treatment of myopia progression in children and adolescents in Chinese population.

The China CHAMP trial involves 18 centers and enrolled 777 patients; The Mini-CHAMP trial involved 16 centers and enrolled 526 patients. The completion of Mini-CHAMP's last patient last visit is an important step forward to the Company's submission of New Drug Application (NDA) in China. On June 7, 2023, the Company announced that its partner - Vyluma Inc. (Vyluma) had announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for NVK002 (low dose atropine 0.01%) as a potential treatment for myopia in children.

NVK002 is currently positioned as the first clinically-proven pharmaceutical product approved for treating the progression of myopia in the world.